PMID- 10531569
OWN - NLM
STAT- MEDLINE
DCOM- 19991123
LR  - 20190905
IS  - 0098-1532 (Print)
IS  - 0098-1532 (Linking)
VI  - 33
IP  - 5
DP  - 1999 Nov
TI  - Disturbance in bone turnover in children with a malignancy at completion of 
      chemotherapy.
PG  - 455-61
AB  - BACKGROUND: Osteoporosis and pathological fractures have been observed in 
      children with a malignancy. The mechanisms of osteopenia in childhood 
      malignancies have not been well established. The purpose of the present study was 
      to evaluate changes in bone turnover and in bone hormonal metabolism in children 
      with a malignancy at completion of their chemotherapy. PROCEDURE: Serum levels of 
      human intact osteocalcin, type I collagen carboxyterminal propeptide (PICP), type 
      I collagen carboxyterminal telopeptide (ICTP), 25-hydroxyvitamin D [25-(OH)-D], 
      1,25-dihydroxyvitamin D [1, 25-(OH)(2)-D], intact parathyroid hormone, 
      insulin-like growth factor I (IGF-I), IGF binding protein 3 (IGFBP-3), alkaline 
      phosphatase, calcium, and phosphate were analyzed in 22 children with acute 
      lymphoblastic leukemia and in 26 children with other malignancies. Results were 
      expressed as Z-scores [mean (95% confidence intervals)] relative to healthy 
      Caucasian-children. RESULTS: The marker of collagen degradation (ICTP) was 
      significantly increased [1.43 (1.10-1.76), P < 0.0001] compared to reference 
      values, whereas the markers of bone formation (PICP, osteocalcin) were not 
      changed [0.07 (-0.55 to 0.49), 0.35 (-0.05 to 0.74), respectively, NS]. Serum 
      25-(OH)-D, 1,25-(OH)(2)-D, and calcium were significantly reduced [-0.65 (-0.87 
      to -0.42), -0.68 (-0.92 to -0. 42), -1.42 (-1.80 to -1.04), P < 0.0001, 
      respectively]. CONCLUSIONS: Disturbance in bone turnover with low serum 
      25-(OH)-D, 1, 25-(OH)(2)-D, and calcium was observed in children with a 
      malignancy at completion of their chemotherapy. A controlled study determining 
      the possible benefits of vitamin D and calcium supplementation on bone turnover 
      could be considered in these patients.
CI  - Copyright 1999 Wiley-Liss, Inc.
FAU - Arikoski, P
AU  - Arikoski P
AD  - Department of Pediatrics, Kuopio University Hospital, Kuopio, Finland. 
      Arikoski@messi.uku.fi
FAU - Kroger, H
AU  - Kroger H
FAU - Riikonen, P
AU  - Riikonen P
FAU - Parviainen, M
AU  - Parviainen M
FAU - Voutilainen, R
AU  - Voutilainen R
FAU - Komulainen, J
AU  - Komulainen J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Med Pediatr Oncol
JT  - Medical and pediatric oncology
JID - 7506654
RN  - 0 (Calcium, Dietary)
RN  - 1406-16-2 (Vitamin D)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Adolescent
MH  - Antineoplastic Combined Chemotherapy Protocols/*adverse effects/therapeutic use
MH  - Bone Diseases, Metabolic/*etiology/prevention & control
MH  - Bone and Bones/*metabolism
MH  - Calcium/*blood/metabolism
MH  - Calcium, Dietary
MH  - Child
MH  - Child, Preschool
MH  - Dietary Supplements
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Infant
MH  - Male
MH  - Neoplasms/*drug therapy/metabolism
MH  - Nutritional Status
MH  - Vitamin D/administration & dosage
EDAT- 1999/10/26 00:00
MHDA- 1999/10/26 00:01
CRDT- 1999/10/26 00:00
PHST- 1999/10/26 00:00 [pubmed]
PHST- 1999/10/26 00:01 [medline]
PHST- 1999/10/26 00:00 [entrez]
AID - 10.1002/(SICI)1096-911X(199911)33:5<455::AID-MPO4>3.0.CO;2-3 [pii]
AID - 10.1002/(sici)1096-911x(199911)33:5<455::aid-mpo4>3.0.co;2-3 [doi]
PST - ppublish
SO  - Med Pediatr Oncol. 1999 Nov;33(5):455-61. doi: 
      10.1002/(sici)1096-911x(199911)33:5<455::aid-mpo4>3.0.co;2-3.